[COMMENT #2] "All the PLPs identified in this study end with an Asp residue and one starts with a Lys residue. While I believe that indeed the cyclization occurs exclusively between N-and C-terminus (especially because the authors did a careful comparison between some extracted PLPs with their synthetic analogs), I wonder if the authors have any other experimental evidence that it is not the side chain of the C-terminal Asp (or in one case the N-terminal Lys) that is involved in the macrocyclization. As the C-terminal Asp is apparently universal in these peptides, this might merit further discussion by the authors."
[RESPONSE #2] The evidence we have of head-to-tail cyclisation and not side chain is that for at least 4 of the PLPs we compared retention time and MS/MS fragmentation of four native and synthetic PLPs. It is possible, but unlikely those with amino-containing side chains could be side chain cyclised by AEP (would be same mass as backbone cyclic) as this reaction has not been observed to be performed by AEP. In the Discussion section titled "Sequencing of PLPs by LC-MS/MS" we have added a paragraph to mention this possibility: (Luckett et al., 1999; Mylne et al., 2011; Elliott et al., 2014) .
Although we matched four synthetic, head-to-tail cyclized PLPs to the native PLP in LC-MS and MS/MS, it has been assumed, based on conservation that all PLPs are head-to-tail cyclic. Some PLPs contain residues with amino groups in their side-chain that could conceivably take the place of the proto-amino terminus in the transpeptidation reaction performed by AEP. Most conspicuous of these is
[COMMENT #3] "The statement about PLPs not being antibacterial is one of the biggest issues I have with this study. The reason is that the authors only tested against a single E. coli strain, which does not justify such a general statement (with regard to the stated lack of antifungal activity, at least three strains were assessed). The authors should either revise that statement or expand their panel of tested organisms. If they want to do the latter, a variety of gram-positive and gram-negative bacteria should be used, of which some are ideally found in the same environment as the plant species from which the respective PLPs were discovered."
[RESPONSE #3] We carried out additional antibacterial activity assays with a wider range of synthetic peptides than before (including some we received recently) and with additional Gram-negative and Gram-positive strains. Consistent with our previous findings, the PLPs tested were not antibacterial. These data are presented as a Supplemental Figure 59 with photographs of the results of the disc diffusion assays we carried out. The results section has been updated also:
Although some studies on orbitides have indicated they possess antibiotic activity, an inspection of LB agar plates after overnight incubation at 37°C showed no inhibition of the growth of the Gram-negative bacteria, Escherichia coli B and Pseudomonas aeruginosa, nor of the Grampositive bacteria, Bacillus cereus and Staphylococcus aureus, by any of the six discs containing between 0.5 μg and 25 μg of synthetic PLP-2, PLP-18 or PLP-20, nor did a negative control disc, treated only with water, inhibit growth (Supplemental Figure 59A-D) . By contrast there was a clear zone of growth inhibition around a positive control disc containing kanamycin, except in the case of P. aeruginosa, which is known to be more resistant to kanamycin than the other bacterial species (Morita et al., 2014) . However, a separate control plate with discs containing larger amounts of kanamycin did show growth inhibition of P. aeruginosa (Supplemental Figure 59E) .
[COMMENT #4] "The fact that some Asteroideae species produce more than one PLP might suggest that these are multicomponent antimicrobials that are only active in combination, but not on their own. This is something already observed in other RiPP classes, and while it cannot be addressed experimentally in this study, it could at least be discussed in the manuscript.
[RESPONSE #4] We have added two sentences to the end of the discussion section on "Anti-Bacterial and Anti-Fungal Assays" stating: "As most Asteroideae species produce more than one PLP, it is possible that they could act as multicomponent antimicrobials that only work in combination, but not on their own. This behaviour has been observed in the two-component bacteriocins produced by lactic acid bacteria (Garneau et al., 2002) [COMMENT #6] "In the introduction, the authors mention recent works that traced the evolutionary history of STFI-1 and other bicyclic peptides to orbitide ancestors. As STFI-1 is a protease inhibitor (a feature also found for other cyclic peptides and other RiPPs like e.g. the microviridins), the authors should consider adding assays where they test their four synthetic PLPs for inhibition of commercially available proteases. Such assays could be performed very quickly and, even if they fail, would be interesting for comparison to STFI-1."
[RESPONSE #6] Whilst it is certainly possible, we felt it improbable that these peptides function as protease inhibitors as they do not have the beta strand structure that is universally found in substrates (and thus inhibitors) of proteases [1] . Furthermore, Alexander Konarev published work showing no evidence of serine protease inhibitors in the Asteraceae (formerly Compositae) with molecular weights below 1,500 Da [2] and many of these specific species either have or (based on the age of the PawL gene) are likely to have PawL1 genes. Finally, as there are many different proteases, it is hard to make any definitive statement without testing many of them against PLPs for inhibitory activity. We would point out that even among the PDPs (the peptide group to which SFTI-1 belongs) very few inhibit trypsin like SFTI-1 does [3] . So, especially due to their lack of beta strand structure found universally in proteases inhibitors, we are reluctant to carry out protease inhibition assays on PLPs as they are likely to be unsuccessful.
[1] Tyndall, Nall, and Fairlie. "Proteases universally recognize beta strands in their active sites." Chemical Reviews 105. [COMMENT #7] "At the beginning of their discussion section, the authors mention that 22 of the undetected peptide sequences had no C-terminal Asp and thus were not being processed by the respective organisms. I would welcome if they could also discuss, if these peptides contain the conserved flanking regions described in Figure 4 or lack them as well."
[RESPONSE #7] To address this comment we analysed all the precursor sequences, whether they made a detectable PLP or not. We found all the precursor sequences, whether a matching PLP was detectable or not, had similar flanking sequences. With this more thorough analysis, we added two new panels to Figure 5 and added the following text to the results:
"The flanking sequences for putative PLPs we could not detect still showed similar conservation to regions in transcripts for PLPs we could detect ( Figure 5D ,E)."
[COMMENT #8] "Furthermore, the authors should comment if there is any evidence of the according preproteins being either evolutionary ancestors from which the PLP-containing preproteins were derived or if they look more like they were PLP-containing proteins at one point, but then got inactivated by random mutation of the C-terminal Asp residue."
[RESPONSE #8] We would suggest that the peptide sequences without the C-terminal Asp have been inactivated by random mutation, as their sequences often differ from typical, expressed PLPs in other ways. They often lack the N-terminal Gly and contain residues that are uncommon in PLPs, such as Ser, His, Met, Trp and Gln. We have added more discussion, speculating that these 22 are derived from PLPmaking PawL1 genes, not ancestors. "Briefly, a gradient elution was run with HPLC-grade solvents (Honeywell) from 5% solvent B to 95% solvent B over 15 min at a flow rate of 300 nL/min using a C18 high capacity nano-LC chip (Part No. G4240-62010, Agilent Technologies) comprising a trapping column (160 nL) and an analytical column (75 µm x 150 mm)"
[COMMENT #10] "The MS2 spectra containing figures are pretty packed with information to a point where they become a bit confusing. While it would be too much effort to change all of these, the authors could at least add some color to Figure 2 and 3 in the main text, to make them more accessible to the reader."
[RESPONSE #10] We did as suggested and in these two figures we have highlighted each ion series using a different colour.
[COMMENT #11] " Figure 4 could benefit from highlighting the bond newly formed during the macrocyclization."
[RESPONSE #11] We have added the head-to-tail bond in the figure as requested (now Figure 5 ).
Reviewer #3
[COMMENT #12] "The methods should contain at least brief details about peptide isolation from seeds. What mass of seeds was extracted? What is an estimate of the peptide yield? It is unclear why the reader is directed to a previous paper when other sections are more clearly described."
[RESPONSE #12] We have added a brief description of the extraction method. The text is now expanded as follows:
Seed peptides were extracted as described by Jayasena et al. (2017) . It is hard to say what the peptide yield was as we did not carry out quantitative mass spectrometry experiments because of the difficulty and expense of finding suitable calibration standards. The mass spectrometry signal strength varied enormously from seed to seed and peptide to peptide. As a comparison, we can say that the synthetic peptides were diluted to a concentration of approximately 5 ng/µL and gave a strong MS signal when 2 µL were injected for LC-MS. From this, we would say the yields of the native peptides were in the nanogram range or possibly below.
[COMMENT #13] "While the NMR structural data has been deposited to the PDB and BMRB, I still think there is value in seeing the NOESY and ROESY data in the Supporting information."
[RESPONSE #13] We have added these spectra to the manuscript. We put one example spectral pair as a figure ( Figure 6 ) and put the rest in the Supporting Information (Supplemental Figures 53-56 Figure 6 ). The same procedure was followed for synthetic . Following this, ROESY peaks (NOESY in the case of PLP-2) were identified and used as restraints for structural modelling.
